Akèy › Kansè Poumon ki pa ti selil › Maryland › Baltimore
Etid klinik pou Kansè Poumon ki pa ti selil nan Baltimore, MD
60 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- ak 3 plis
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Ap rekriteFaz 3
- Ascension Saint Agnes Hospital, Baltimore
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Local Institution - 0123, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #14, Baltimore
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Ap rekriteFaz 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Johns Hopkins University, Baltimore
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- Research Site, Baltimore
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Johns Hopkins University of Medicine, Baltimore
DK222 Study at Hopkins
Ap rekriteFaz 1
- Johns Hopkins Hospital, Baltimore
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi lwen
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Maryland, Baltimore
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Towson · 8 mi lwen
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of Maryland, Baltimore
- Johns Hopkins Bayview Medical Center, Baltimore
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Local Institution - 0505, Annapolis · 22 mi lwen
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Annapolis · 22 mi lwen
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Baltimore
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- Local Institution - 0702, Annapolis · 22 mi lwen
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Ap rekriteFaz 2
- University of Maryland Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Medstar Franklin Square, Baltimore
- ak 1 plis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Baltimore
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- Johns Hopkins, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- United Theranostics, Glen Burnie · 9 mi lwen
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Ap rekriteFaz 2
- John Hopkins Medical Center, Baltimore
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Johns Hopkins Bayview Medical Center, Baltimore
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Baltimore
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Ap rekriteFaz 3
- University of Maryland, Baltimore
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Ap rekriteFaz 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Ap rekriteFaz 1/2
- Johns Hopkins University, Baltimore
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- University of Maryland, Baltimore
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Research Site, Baltimore
GCC 2546- Motion Management
Ap rekrite
- University of Maryland Greenebaum Cancer Center, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Ap rekriteFaz 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · 9 mi lwen
- United Theranostics - Chesapeake, Glen Burnie · 9 mi lwen
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Johns Hopkins Hospital /ID# 254056, Baltimore
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi lwen
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Johns Hopkins University, Baltimore
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Johns Hopkins Hospital, Baltimore
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Johns Hopkins University, Baltimore
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Baltimore
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center- Tate Cancer Center, Glen Burnie · 9 mi lwen
- ak 1 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Saint Agnes Hospital, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi lwen
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 2
- University of Maryland Medical Center, Baltimore
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Johns Hopkins University, Baltimore
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Ap rekriteFaz 1
- Research Site, Baltimore
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Ap rekriteFaz 1
- Johns Hopkins University, Baltimore
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · 8 mi lwen
- ak 1 plis
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- University of Maryland, Baltimore
- Johns Hopkins University, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi lwen
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Ap rekriteFaz 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan Baltimore
- Kansè nan tete47 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè kolorektal31 etid
- Kansè pankreyas31 etid
- Kansè Metastatik28 etid
- Obèsite25 etid
- Ensifizyans kadyak24 etid
- Kansè vejik24 etid
- Akidan serebavaskilè22 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.